Urology is ripe to accelerate its consolidation wave with institutional capital flowing into the specialty, according to a urology M&A industry report released by the Healthcare Provider Services investment banking team from Brown Gibbons Lang & Company (BGL).
Inside the report, BGL’s Healthcare Provider Services team highlights tailwinds in the industry, the growing number of investor-backed platforms, and shares commentary obtained through exclusive executive interviews discussing topics ranging from the demand outlook and recruiting to value-based care and the growth in ancillary services.
- “Urology does benefit from the big demographic plays,” said Marshal Salomon, CEO of Unio Health Partners, and a report participant, speaking to the graying U.S. population which is contributing to increased demand for urological care.
- “Urology is as strong as any specialty because there are so many ancillary opportunities. You’ve got imaging, pathology, radiation, and surgery centers,” said Michael Shannon, CEO of First Urology.
The healthcare investment banking team at BGL expects M&A activity in urology to accelerate substantially over the coming years. The ancillary-rich specialty, with high fragmentation, ample supply, and demand tailwinds, has attracted the attention and capital of private equity, with several platforms that have launched over the past several years, all of which are actively seeking acquisitions to increase scale and geographic reach.